Sanofi, Kali Sign Deal For Trispecific Antibody In Autoimmune Disease
Deal Snapshot: The French drugmaker gains rights to the anti-CD19xBCMAxCD3 candidate, which is designed to have the benign safety profile considered especially important in immunology.
Scrip - March 23, 2026

EU’s Green Agenda Moves Back To Center Stage
Two lawyers within EU legal chamber Axon Lawyers created a Green Team to cope with the rise in EU Green Deal and related environmental sustainability and compliance needs for medtechs. One of them, Jilles van der Hoek, explains why manufacturers should be getting a jump on future requirements.
Medtech Insight - March 23, 2026

Stock Watch: Weakness In Numbers
The formation of the European Life Sciences Coalition by venture capital firms reflects investor strain rather than renewed confidence in European biotech. The outcome for syndicates of companies and investors has not always been good.
Scrip - March 23, 2026

Stada Evaluating CHC Acquisition Targets Globally
Stada is reviewing potential M&A for its Consumer Healthcare business, which last year grew its sales despite a weak cough & cold season.
HBW Insight - March 23, 2026

India’s Generic Semaglutide Onslaught: Discounts, Disruption And What KOLs Want
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule, setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
Generics Bulletin - March 23, 2026

IPA Europe: Probiotics Could Save EU Health Systems Over €10bn Per Year
Just a 1% improvement thanks to probiotic use in areas like antibiotic?associated diarrhea, respiratory tract health, oral health, women’s health, lactose digestion, and mental wellbeing could generate significant savings for Europe's strained health systems.
HBW Insight - March 23, 2026

Apogee’s Atopic Dermatitis Drug Shows Promise, But Can It Challenge Dupixent, Ebglyss?
With Phase III plans underway and Part B data from its APEX trial due in 2026, Apogee is banking on zumilokibart's extended dosing advantage compared with rivals.
Scrip - March 23, 2026

‘This Year Is A Pivot To Offense’ – AAM’s Murphy Steps Up Lobbying Efforts In US
After an eventful 2025 that saw the US off-patent industry chalk up wins on tariffs and biosimilar streamlining, AAM president and CEO John Murphy III talks to Generics Bulletin about how the association will be stepping up its lobbying efforts in a US election year.
Generics Bulletin - March 23, 2026

Henlius Accelerates Global Push In Checkpoint Biosimilars
Henlius is advancing its nivolumab biosimilar HLX18 into Chinese trials, as it expands a global oncology pipeline. In 2025, the firm’s strong revenue growth was offset by rising R&D investment amid increasing contributions from overseas partnerships.
Generics Bulletin - March 23, 2026

In Medtech, AI Is No Longer An Add-On, It’s Becoming Part of Operations, LSI Panelists Said
AI in medtech has moved from “experimentation into expectation,” leaders from Dexcom, Boston Scientific and Ajax Health said at the LSI conference. The execs advised start-ups to focus on embedding AI thoughtfully for real solutions, listening to customer feedback, and instilling a learning culture.
Medtech Insight - March 23, 2026

Practicalities For AI-Enabled Devices As Digital (R)evolution Picks Up Pace
AI-enabled tools deliver faster radiology reads, clinical decision-support, personalized treatment insights and continuous patient monitoring, but a new report from Firefinch Software and IMed Consultancy advises device developers how to enter and stay in this rapidly growing market.
In Vivo - March 23, 2026

India’s Semaglutide Gx Onslaught: Discounts, Disruption And What KOLs Want
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
Scrip - March 23, 2026

Chugai’s Narrow Partnering Strategy Means Less Competition
Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.
In Vivo - March 23, 2026

Dizal’s Zegfrovy Snags World-First Phase III Win As Oral Option For Rare-Type NSCLC
Dizal's Zegfrovy (sunvozertinib), already approved in the US and China for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations, triumphs in the WU-KONG28 Phase III study in the first-line setting.
Scrip - March 23, 2026

PDUFA VIII: US FDA Tries To Resolve ‘America First’ Impasse
Agency offered to drop annual IND fees for sponsors not conducting Phase I trials in US, but industry still raised several concerns about fee incentives for onshoring clinical development.
HBW Insight - March 23, 2026

Consumer Healthcare M&A, Investment Advisor Receives CHPA Lifetime Achievement Award
At opening session of CHPA’s annual Self-Care Leadership Summit on March 17 in Orlando, it presented Fuad Sawaya its highest honor named for Ivan Combe, an industry pioneer who served on its board from 1958 until 2000.
HBW Insight - March 23, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: many blockbusters to fade this year: semaglutide’s India reckoning; multinationals look beyond simple China licensing; Almirall eyes China dermatology assets; EU urged to restore biopharma competitiveness.
Scrip - March 23, 2026